Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Molecular Transfer Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, RAGHU, GANAPATHIRAM, who is also the busiest examiner for the company. The portfolio is currently limited to 1 distinct art unit, which implies a specific technical focus within the broader biotechnology field. With 1 pending office action, the company is navigating the examination process for its latest innovation.
Because RAGHU, GANAPATHIRAM is responsible for the 1 busiest examiner pending action, the prosecution effort is entirely concentrated. This lack of diversification means the outcome of the 1 pending office action relies on the specific feedback of a single examiner. However, the presence of only 1 distinct art unit means that the prosecution team only needs to adapt to the procedural nuances of one departmental group. This allows for a highly targeted approach to resolving the 1 pending office action while ensuring technical consistency with the standards of the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAGHU, GANAPATHIRAM | 1 | 73.8% | +26.3% |
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18771323 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | RAGHU, GANAPATHIRAM | — |
| 18747146 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | KELLY, ROBERT M | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18771323 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | RAGHU, GANAPATHIRAM | 1652 | §102§103DPOther | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18747146 | POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | KELLY, ROBERT M | 1638 | Other | Non-Final OA | — | Pending | Jun 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMolecular Transfer Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Ganapathiram Raghu has the most, with 1 of Molecular Transfer Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.